|
|
| New Whitepaper: Insights into MSC-Based Therapies | Discover key advancements in MSC-based therapies with insights from Corning's Field Application Scientists. Explore methods for MSC isolation, production considerations, media options, cell expansion technologies, and cGMP manufacturing. Gain valuable learnings from collaborations with academic researchers, biotech, and pharmaceutical companies, featuring real-world case studies. Whether you're scaling for clinical applications or advancing research, this whitepaper provides actionable strategies to optimize MSC production and push the boundaries of therapeutic development. |
|
|
|
|
By Jennifer Chain, Ph.D., CABP, cellular starting material expert | The so-called "last mile" in cell therapy gets a lot of attention. What about the first mile, the journey cells take between the donor and the manufacturing site? | |
|
|
|
|
|
|
|
| Vial Adapter Considerations For Cell And Gene Therapy Applications | Article | By Krishnendu Khan, Henry Nguyen, et al., West Pharmaceutical Services, Inc. | Review features that need to be considered to choose a vial adapter for cell and gene therapy drug products and a case study where vial adapter transfer devices have been used to extract lentiviruses. |
|
|
|
|
|
|
|
|
|
|
| Webinar: Enhancing viral vector sterile filtration: process efficiency and GMP alignment | Sterile filtration is vital to viral vector manufacturing success—impacting yield, quality, and compliance. Join Cytiva to explore advances with Supor™ EKV and Supor™ Prime filters for AAV and lentivirus workflows. Learn how optimized filtration strategies boost recovery and streamline downstream operations, plus gain practical guidance on implementing PUPSIT in line with EU GMP Annex 1. Click here to learn more. |
|
|
|
|
|
|
|
|
|
| Advancing the Future of Cell & Gene Therapy | This 11-12 November, Cell 2025 unites 1,000+ leading experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development timelines. Gain practical strategies across cell culture, therapy development, and CGT manufacturing, and hear from world-renowned leaders Bobby Gaspar (CEO, Orchard Therapeutics), Christof Von Kalle, (Director & BIH Chair, Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now |
|
|
| Connect With Cell & Gene: |
|
|
|